title: Evaluation of cytokines as adjuvants of infectious bovine keratoconjunctivitis vaccines.
abstract: In this work two cytokines were used in combination with inactivated bacteria (bacterin) to test the bovine conjuctival immune response to the pathogen Moraxella bovis, the causative agent of Infectious bovine keratoconjunctivitis (IBK). Treatments using the bacterin vaccine combined with interleukin-2 and interferon-α as adjuvants (Group A), the bacterin vaccine only (Group B), and controls without treatment (Group C), were applied by ocular spraying to evaluate the local immune response in the corneal structure of cattle experimentally infected with M. bovis. Six weeks after infection, 14 out of a total of 34 animals presented different corneal lesions; 9 corresponding to the control group C, 4 to the group B and only one to the group A. According to the clinical manifestations, a numeric score was calculated. Control animals presented the highest score value (12 points), followed by group B (7.5 points) and group A (1 point). These results suggest that the addition of cytokines to M. bovis treatments can reduce not only eye injuries caused by IBK but also the number of diseased animals.
authors.affiliation: Centro de Inmunoterapia Veterinaria (CIV), Buenos Aires, Argentina.
authors.forename: Fabio A
authors.initials: FA
authors.lastname: di Girolamo
authors.forename: Diego Jorge
authors.initials: DJ
authors.lastname: Sabatini
authors.forename: Raúl A
authors.initials: RA
authors.lastname: Fasan
authors.forename: Maia
authors.initials: M
authors.lastname: Echegoyen
authors.forename: Mauro
authors.initials: M
authors.lastname: Vela
authors.forename: Claudio A
authors.initials: CA
authors.lastname: Pereira
authors.forename: Pablo
authors.initials: P
authors.lastname: Maure
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D016207:Cytokines / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007639:Keratoconjunctivitis, Infectious / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D016955:Moraxella bovis / Q000276:immunology; D045828:Moraxellaceae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*
chemical_list: D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D016207:Cytokines; D016898:Interferon-alpha; D007376:Interleukin-2